Taro Pharmaceutical Industries (NYSE:TARO) Earns Strong-Buy Rating from Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Taro Pharmaceutical Industries (NYSE:TAROGet Free Report) in a research report issued on Thursday. The brokerage set a “strong-buy” rating on the stock.

Taro Pharmaceutical Industries Stock Up 0.4 %

NYSE:TARO opened at $42.86 on Thursday. Taro Pharmaceutical Industries has a 12 month low of $32.67 and a 12 month high of $45.76. The company’s 50-day moving average price is $42.38 and its two-hundred day moving average price is $41.57. The firm has a market cap of $1.61 billion, a PE ratio of 29.76 and a beta of 0.56.

Hedge Funds Weigh In On Taro Pharmaceutical Industries

A number of large investors have recently modified their holdings of the stock. Brandes Investment Partners LP raised its stake in shares of Taro Pharmaceutical Industries by 0.7% during the fourth quarter. Brandes Investment Partners LP now owns 475,741 shares of the company’s stock worth $19,876,000 after buying an additional 3,253 shares during the last quarter. Invesco Ltd. bought a new stake in shares of Taro Pharmaceutical Industries during the third quarter worth approximately $9,995,000. UBS Group AG raised its stake in shares of Taro Pharmaceutical Industries by 56.6% during the third quarter. UBS Group AG now owns 54,175 shares of the company’s stock worth $2,043,000 after buying an additional 19,588 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Taro Pharmaceutical Industries by 5.7% during the first quarter. Vanguard Group Inc. now owns 53,729 shares of the company’s stock worth $2,275,000 after buying an additional 2,889 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in Taro Pharmaceutical Industries by 1.4% in the third quarter. Bank of New York Mellon Corp now owns 22,223 shares of the company’s stock valued at $838,000 after purchasing an additional 307 shares in the last quarter. 91.40% of the stock is currently owned by institutional investors and hedge funds.

About Taro Pharmaceutical Industries

(Get Free Report)

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products.

See Also

Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.